test44
https://www.cytel.com/blog/addressing-critical-unmet-oncology-needs-in-the-era-of-precision-medicine
May 23, 2018
Our Industry Voices series showcases our clients’ innovative work and breakthrough therapeutics in oncologic..
Read article
test44
https://www.cytel.com/blog/industry-voices-rewriting-oncology-textbook
May 16, 2018
Our Industry Voices series showcases our clients’ innovative work and breakthrough therapeutics in oncologic..
Read article
test44
https://www.cytel.com/blog/innovative-oncology-designs-practice
May 9, 2018
As we prepare to head to ASCO in under a month's time, we are pleased to share a new ebook that showcases some key..
Read article
test44
https://www.cytel.com/blog/cross-study-efficiencies-in-biometrics-outsourcing
August 2, 2017
As a biometrics -focused CRO, Cytel regularly works across a program of studies, providing data consistency, and..
Read article
test44
https://www.cytel.com/blog/are-adaptive-designs-the-answer-oncology-development
July 26, 2017
Sadly, clinical development of anti-cancer therapeutics faces particularly high rates of failure, even in the context..
Read article
test44
https://www.cytel.com/blog/inside-the-oncology-statistician-toolkit
February 9, 2017
In this blog, Adam Hamm, PhD, Director Biostatistics at Cytel shares some of the most important knowledge he uses..
Read article
test44
https://www.cytel.com/blog/accelerating-development-combined-sad-mad
January 30, 2017
Single ascending dose (SAD) and multiple ascending dose (MAD) studies are typically the first in human studies. They..
Read article
test44
https://www.cytel.com/blog/dm-challenges-oncology-studies
April 26, 2016
In this blog we’ll highlight some unique challenges that are encountered from a Data Management perspective when..
Read article
test44
https://www.cytel.com/blog/dual-agent-dose-escalation
April 22, 2016
FDA draft guidance on “Co development of two or more unmarketed investigational drugs for use in combination” notes..
Read article
